Literature DB >> 25234580

Can biomarkers differentiate pain and no pain subgroups of nonverbal children with cerebral palsy? A preliminary investigation based on noninvasive saliva sampling.

Frank J Symons1, Issam ElGhazi, Brian G Reilly, Chantel C Barney, Leah Hanson, Angela Panoskaltsis-Mortari, Ian M Armitage, George L Wilcox.   

Abstract

OBJECTIVE: Assessing and treating pain in nonverbal children with developmental disabilities are a clinical challenge. Current assessment approaches rely on clinical impression and behavioral rating scales completed by proxy report. Given the growing health relevance of the salivary metabolome, we undertook a translational-oriented feasibility study using proton nuclear magnetic resonance (NMR) spectroscopy and neuropeptide/cytokine/hormone detection to compare a set of salivary biomarkers relevant to nociception.
DESIGN: Within-group observational design.
SETTING: Tertiary pediatric rehabilitation hospital.
SUBJECTS: Ten nonverbal pediatric patients with cerebral palsy with and without pain.
METHODS: Unstimulated (passively collected) saliva was collected using oral swabs followed by perchloric acid extraction and analyzed on a Bruker Avance 700 MHz NMR spectrometer. We also measured salivary levels of several cytokines, chemokines, hormones, and neuropeptides.
RESULTS: Partial least squares discriminant analysis showed separation of those children with/without pain for a number of different biomarkers. The majority of the salivary metabolite, neuropeptide, cytokine, and hormone levels were higher in children with pain vs no pain.
CONCLUSIONS: The ease of collection and noninvasive manner in which the samples were collected and analyzed support the possibility of the regular predictive use of this novel biomarker-monitoring method in clinical practice. Wiley Periodicals, Inc.

Entities:  

Keywords:  Developmental Disability; Metabolite; Nuclear Magnetic Resonance (NMR); Pain; Partial Least Squares Discriminant Analysis (PLS-DA); Saliva

Mesh:

Substances:

Year:  2014        PMID: 25234580      PMCID: PMC4332832          DOI: 10.1111/pme.12545

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  17 in total

1.  Challenge of pain in the cognitively impaired.

Authors:  H H Abu-Saad
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

Review 2.  Brain imaging of clinical pain states: a critical review and strategies for future studies.

Authors:  Ron Kupers; Henrik Kehlet
Journal:  Lancet Neurol       Date:  2006-12       Impact factor: 44.182

Review 3.  Perspectives on pain and intellectual disability.

Authors:  F J Symons; S K Shinde; E Gilles
Journal:  J Intellect Disabil Res       Date:  2008-01-16

4.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

5.  Dorsal root ganglion neurons innervating skeletal muscle respond to physiological combinations of protons, ATP, and lactate mediated by ASIC, P2X, and TRPV1.

Authors:  Alan R Light; Ronald W Hughen; Jie Zhang; Jon Rainier; Zhuqing Liu; Jeewoo Lee
Journal:  J Neurophysiol       Date:  2008-05-28       Impact factor: 2.714

6.  Parent evaluation of spasticity treatment in cerebral palsy using botulinum toxin type A.

Authors:  Frank J Symons; Patrick F Rivard; Andrea C Nugent; Raymond C Tervo
Journal:  Arch Phys Med Rehabil       Date:  2006-12       Impact factor: 3.966

Review 7.  Prolactin, immunoregulation, and autoimmune diseases.

Authors:  L J Jara; C Lavalle; A Fraga; C Gómez-Sanchez; L H Silveira; P Martínez-Osuna; B F Germain; L R Espinoza
Journal:  Semin Arthritis Rheum       Date:  1991-04       Impact factor: 5.532

8.  Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model.

Authors:  Sujatha Kannan; Hui Dai; Raghavendra S Navath; Bindu Balakrishnan; Amar Jyoti; James Janisse; Roberto Romero; Rangaramanujam M Kannan
Journal:  Sci Transl Med       Date:  2012-04-18       Impact factor: 17.956

Review 9.  Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.

Authors:  C Bole-Feysot; V Goffin; M Edery; N Binart; P A Kelly
Journal:  Endocr Rev       Date:  1998-06       Impact factor: 19.871

10.  Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation.

Authors:  Jarrad M Scarlett; Xinxia Zhu; Pablo J Enriori; Darren D Bowe; Ayesha K Batra; Peter R Levasseur; Wilmon F Grant; Michael M Meguid; Michael A Cowley; Daniel L Marks
Journal:  Endocrinology       Date:  2008-06-26       Impact factor: 4.736

View more
  5 in total

1.  Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.

Authors:  Hershel Raff; Jonathan M Phillips; Pippa M Simpson; Steven J Weisman; Keri R Hainsworth
Journal:  Pain Rep       Date:  2020-07-22

2.  Initial Observations of Salivary Brain-Derived Neurotrophic Factor Levels in Rett Syndrome.

Authors:  Breanne Byiers; Chantel Barney; Michael Ehrhardt; Angela Panoskaltsis-Mortari; Timothy Feyma; Arthur Beisang; Frank J Symons
Journal:  Pediatr Neurol       Date:  2017-12-08       Impact factor: 3.372

3.  Pain in Intellectually Disabled Children: Towards Evidence-Based Pharmacotherapy?

Authors:  Abraham J Valkenburg; Tom G de Leeuw; Monique van Dijk; Dick Tibboel
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.022

4.  Catestatin and vasostatin concentrations in healthy dogs.

Authors:  Thanikul Srithunyarat; Ragnvi Hagman; Odd V Höglund; Ulf Olsson; Mats Stridsberg; Supranee Jitpean; Anne-Sofie Lagerstedt; Ann Pettersson
Journal:  Acta Vet Scand       Date:  2017-01-03       Impact factor: 1.695

Review 5.  Physiological Measures of Acute and Chronic Pain within Different Subject Groups: A Systematic Review.

Authors:  H Korving; P S Sterkenburg; E I Barakova; L M G Feijs
Journal:  Pain Res Manag       Date:  2020-09-03       Impact factor: 3.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.